Research Article

Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease

Huiling Huang,1 Chunmei Zeng,2 Yuedong Ma,1 Yili Chen,1 Cong Chen,1 Chen Liu,1 and Yugang Dong1,3

1Department of Cardiology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2Department of Cardiology, Yulin City First People’s Hospital No. 495 Jiao Yu Zhong Road, Yuzhou, Yulin, Guangxi 537000, China
3Key Laboratory on Assisted Circulation, Ministry of Health, Guangzhou 510080, China

Correspondence should be addressed to Yugang Dong; 2319133979@qq.com

Received 28 May 2015; Revised 20 August 2015; Accepted 23 August 2015

Academic Editor: Benoit Dugue

Copyright © 2015 Huiling Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Coronary artery disease (CAD) and its related chronic complications continue to be the leading cause of death worldwide [1]. Chronic kidney disease (CKD) has been recognized as a major and independent risk factor for cardiovascular diseases (CVD) [2–5]. Instead of progressing to end-stage renal disease (ESRD), most CKD patients die of CVD, while only 3.1% of patients progress to ESRD [6]. On the other hand, patients with CAD were frequently shown to have impaired renal function, which may contribute to worse clinical outcomes [7–10].

Statins, a family of HMG-CoA reductase inhibitors that lower cholesterol levels, are the most widely prescribed class of drugs; they are reported to reduce cardiovascular events by 25% to 45% [11]. They are well tolerated and are believed to have minimal adverse effects. These drugs are most effective for treating CVD as a secondary prevention strategy [12]. In patients with mild-to-moderate CKD, statins were found to be effective for primary prevention and to reduce cardiovascular risk. They have been reported to slow or even reverse the decline in renal function in patients with CKD, independent of lipid lowering. Multiple landmark clinical trials have demonstrated modest renoprotection with statins [13]. Thus, it is believed that statins have both cardiovascular and renal benefits in prevention and treatment.

Long-term persistence of statin therapy is essential for secondary prevention of CVD. Shalev et al. reported that better continuity of statin treatment provided an ongoing reduction in mortality among patients with and without a known history of CVD [14]. The renoprotective effect of statins on CKD patients is also shown to be dependent on the duration...
of treatment [14, 15]. To date, however, no study has compared the effects of long-term statin therapy in CAD patients with or without CKD after coronary artery revascularization and CKD patients, nor are there any published data available from China to address the effects of long-term statin therapy in patients with concomitant CAD and CKD. Therefore, we conducted a retrospective analysis to compare the effects of long-term statin use on cardiovascular events and mortality in three groups of Chinese patients: CAD only, CAD + CKD, and CKD only.

2. Methods

Hospitalization records of patients with CAD + CKD, CAD only, or CKD only were reviewed for demographic data, cardiovascular end points, and long-term regular use of statins. Inpatients were selected from the First Affiliated Hospital of Sun Yat-sen University between January 2005 and December 2008 if they were diagnosed with CAD by coronary angiogram (CAG). Patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² were considered to have concomitant CKD (n = 328), while a total of 242 CAD patients with eGFR ≥ 60 mL/min/1.73 m² and 147 CKD-only patients (eGFR < 60 mL/min/1.73 m²) were randomly selected for the control groups. The diagnosis of CAD was confirmed with coronary angiography for all patients. Patients received a stent graft or coronary artery bypass grafting surgery according to the extent of their lesions. Recorded parameters included age, gender, height, weight, history of hypertension and diabetes mellitus, and various biochemical indexes: serum creatinine, blood urea nitrogen (BUN), glycated hemoglobin (HbA1C), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-1 (ApoA-I), apolipoprotein B (ApoB), apolipoprotein AI/B (ApoA-I/B), apolipoprotein E (apoE), and lipoprotein (a) (Lp-a). The results of CAG and cardiac color ultrasound and the drug therapy administered during the hospitalization were recorded and analyzed.

The participants were followed up retrospectively by medical records and telephone and were divided into the long-term statin group and statin-discontinuation (no statin) group based on the use of statins by the proportion of days covered. The primary end points (death, including cardiovascular and noncardiovascular mortality), secondary end points (revascularization, angina, nonfatal myocardial infarction, heart failure, ischemic stroke, and hemorrhagic stroke), and the most recent test results for serum creatinine, BUN, and serum lipids before the occurrence of the primary end point events were recorded. Long-term statin users were defined according to the study by Chodick et al. [16]: patients who had taken medication not less than 50% of the follow-up time minus 30 days to the end of follow-up. Otherwise, the patients were categorized into the no-statin group.

We used a simplified MDRD equation, which is more suitable for Chinese people, to evaluate kidney function: 186 × (serum creatinine)⁻¹.¹⁵⁴ × Age⁻₀.²⁰³ × (0.742 for female) [17]. The serum creatinine level was the first measurement result after the patient’s admission to the hospital. The staging of renal function was categorized according to the K/DOQI guidelines: stage 3 is a moderate reduction in GFR (30–59 mL/min/1.73 m²), stage 4 is a severe reduction in GFR (15–29 mL/min/1.73 m²), and stage 5 is established kidney failure (GFR < 15 mL/min/1.73 m² or ESRD period) [18]. Acute myocardial infarction, angina, and heart failure were diagnosed according to the 2008 European Society of Cardiology guidelines. Stroke was diagnosed by the 2010 Chinese guidelines for diagnosis and treatment of acute ischemic stroke [19].

Exclusion criteria included the following: (1) past diagnosis of CAD by coronary angiography in other hospitals; (2) long-term use of statins or other lipid-lowering drugs prior to admission; (3) incomplete data for lipid levels (TC, TG, HDL-C, LDL-C, ApoA-I, ApoB, and ApoA-I/B) during hospitalization; (4) patients who died during the hospitalization; (5) patients suffering from major diseases, such as severe liver disease and cancer, and expected to survive less than 3 months.

2.1. Statistical Analysis. The demographic and clinical characteristics were summarized by descriptive statistics. Continuous and categorical data were presented as mean ± standard deviation (SD) and number (%), respectively. For continuous variables, one-way between-groups ANOVAs were used to assess group differences. Comparisons of categorical variables were performed by the Chi-square test or the Fisher exact test. A major adverse cardiovascular event (MACE) was defined as a composite endpoint including cardiovascular events and all-cause death. The long-term event-free rate was estimated using Kaplan-Meier curves, and the log-rank test was used to identify significant differences in survival rates across the three groups. To identify the factors that might affect the incidence of MACE, a univariate Cox proportional hazard model was developed. To determine independent predictors for MACE, a multivariate Cox regression analysis was developed with the significant predictors (P < 0.05) and the marginally significant ones (P < 0.10) from the univariate model.

3. Results

3.1. Patients’ Characteristics. A total of 717 patients were examined in this research. The CAD + CKD group included 328 patients. The CAD-only and CKD-only groups had 242 and 147 patients, respectively. CKD was present in 57.5% of the CAD patients. Table 1 summarizes the characteristics of patients in the three groups. The CAD + CKD group included the oldest patients. Female gender was found more often in the CKD group. Of note, all patients in the CKD-only group had stage 5 renal disease. Hypertension and myocardial infarction were more common in the CAD + CKD group, whereas smoking and angina pectoris were found more often in the CAD group. The ejection fraction was the lowest in the CAD + CKD group. There were significant differences in concomitant medications, such as calcium-channel blockers, angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARB), β-blockers, and aspirin across the three groups. There was also a significant difference in statin therapy: more than 90% of CAD patients with
Disease Markers

Table 1: Patients’ characteristics.

| Variables                              | CAD + CKD (n = 328) | CAD (n = 242) | CKD (n = 147) | P value |
|----------------------------------------|---------------------|---------------|---------------|---------|
| Characteristics                        |                     |               |               |         |
| Age (years)                            | 69.7 ± 8.4          | 61.6 ± 10.5   | 53.6 ± 17.8   | <0.001  |
| BMI (kg/m²)                            | 24.2 ± 2.2          | 23.2 ± 2.2    | 23.3 ± 2.3    | <0.001  |
| Male                                   | 232/328 (70.7)      | 171/242 (70.7)| 64/147 (43.5) | <0.001  |
| Hypertension                           | 246/328 (75.0)      | 132/242 (54.5)| 83/147 (56.3) | <0.001  |
| Diabetes mellitus                      | 88/328 (26.8)       | 71/242 (29.3) | 42/147 (28.6) | 0.843   |
| Smoking                                | 150/328 (47.5)      | 123/242 (50.8)| 25/147 (17.0) | <0.001  |
| Myocardial infarction                  | 186/328 (56.7)      | 114/242 (47.1)| 0/147 (0)     | <0.001  |
| Angina pectoris                         | 133/328 (40.5)      | 123/242 (50.8)| 0/147 (0)     | <0.001  |
| Stroke                                 | 20/328 (6.1)        | 14/242 (5.8)  | 8/147 (5.4)   | 0.992   |
| Ejection fraction                      | 61.8 ± 14.2         | 65.6 ± 8.8    | 63.2 ± 12.7   | 0.017   |
| Statin therapy                         | 301/328 (91.8)      | 226/242 (93.4)| 68/147 (46.3) | <0.001  |
| Concomitant medications                |                     |               |               |         |
| Calcium-channel blocker                | 115/328 (35.1)      | 58/225 (25.8) | 75/147 (51.0) | 0.004   |
| ACEI                                   | 148/328 (45.1)      | 103/242 (42.6)| 28/147 (19.0) | 0.002   |
| ARB                                    | 119/328 (36.3)      | 83/242 (34.3) | 77/147 (52.4) | 0.041   |
| β-blocker                              | 236/328 (72.0)      | 190/242 (78.5)| 44/147 (29.9) | <0.001  |
| Loop diuretic                          | 50/328 (15.3)       | 13/121 (10.7) | 14/147 (9.5)  | 0.36    |
| Aspirin                                | 302/328 (92.1)      | 228/242 (94.2)| 44/147 (29.9) | <0.001  |
| Clinical parameters                    |                     |               |               |         |
| Total cholesterol (mmol/l)             | 4.7 ± 1.2           | 4.8 ± 1.1     | 6.5 ± 2.9     | <0.001  |
| LDL-C (mmol/l)                         | 9.7 ± 119.1         | 4.2 ± 17.9    | 3.9 ± 2.4     | 0.746   |
| HDL-C (mmol/l)                         | 1.0 ± 0.3           | 1.0 ± 0.3     | 1.2 ± 0.4     | <0.001  |
| Triglycerides (mmol/l)                 | 1.6 ± 1.0           | 1.7 ± 1.1     | 2.4 ± 1.5     | <0.001  |
| HbA1c (%)                              | 6.4 ± 1.2           | 6.6 ± 1.4     | 7.8 ± 2.1     | <0.001  |
| Glucose (mmol/l)                       | 7.2 ± 4.5           | 6.5 ± 4.1     | 14.0 ± 55.3   | 0.014   |
| SBP (mmHg)                             | 136.8 ± 30.0        | 130.1 ± 17.7  | 138.3 ± 22.4  | 0.006   |
| DBP (mmHg)                             | 78.0 ± 15.9         | 78.9 ± 11.2   | 73.5 ± 10.0   | 0.041   |
| BUN (mmol/l)                           | 8.8 ± 4.3           | 5.6 ± 1.5     | 12.3 ± 6.5    | <0.001  |
| Serum creatinine (μmol/l)              | 155.0 ± 111.8       | 80.5 ± 15.3   | 275.4 ± 205.9 | <0.001  |
| ApoA-I (g/l)                           | 1.3 ± 3.9           | 1.0 ± 0.3     | 1.3 ± 0.4     | 0.588   |
| ApoB (g/l)                             | 1.0 ± 2.3           | 0.9 ± 0.2     | 1.0 ± 0.4     | 0.638   |
| ApoA-I/B                               | 1.3 ± 0.5           | 1.5 ± 2.8     | 1.4 ± 0.7     | 0.381   |
| ApoE (ng/dl)                           | 43.6 ± 18.7         | 43.9 ± 26.0   | 97.7 ± 590.3  | 0.119   |
| Lp (a) (ng/ml)                         | 383.1 ± 327.2       | 376.2 ± 429.3 | 372.3 ± 395.6 | 0.955   |
| Clinical parameters at final observation|                     |               |               |         |
| Total cholesterol (mmol/l)             | 4.8 ± 1.3           | 4.4 ± 1.1     | 5.0 ± 1.2     | <0.001  |
| LDL-C (mmol/l)                         | 2.9 ± 1.1           | 2.7 ± 0.9     | 3.1 ± 1.0     | 0.005   |
| HDL-C (mmol/l)                         | 1.1 ± 0.3           | 1.1 ± 0.3     | 1.1 ± 0.2     | 0.551   |
| Triglycerides (mmol/l)                 | 1.6 ± 1.0           | 1.6 ± 1.0     | 1.7 ± 1.0     | 0.69    |
| HbA1c (%)                              | 6.6 ± 1.2           | 6.8 ± 1.3     | 5.9 ± 0.7     | 0.029   |
| Glucose (mmol/l)                       | 7.1 ± 3.0           | 6.4 ± 2.1     | 6.5 ± 2.3     | 0.011   |
| SBP (mmHg)                             | 138.2 ± 27.7        | 128.7 ± 16.1  | 134.7 ± 22.1  | <0.001  |
| DBP (mmHg)                             | 78.1 ± 13.9         | 78.2 ± 10.9   | 82.4 ± 10.7   | 0.074   |
| BUN (mmol/l)                           | 10.6 ± 7.2          | 6.0 ± 1.7     | 13.9 ± 6.8    | <0.001  |
| Serum creatinine (μmol/l)              | 225.1 ± 168.8       | 83.6 ± 20.9   | 349.1 ± 255.0 | <0.001  |
| ApoA-I (g/l)                           | 1.6 ± 6.7           | 1.2 ± 0.5     | 1.1 ± 0.3     | 0.570   |
| ApoB (g/l)                             | 0.9 ± 0.3           | 0.8 ± 0.2     | 1.0 ± 0.4     | <0.001  |
| ApoA-I/B                               | 1.4 ± 0.6           | 1.6 ± 0.7     | 1.3 ± 0.6     | <0.001  |
| ApoE (ng/dl)                           | 43.4 ± 28.4         | 40.9 ± 16.6   | 53.3 ± 66.6   | 0.010   |
| Lp (a) (ng/ml)                         | 444.5 ± 1003.7      | 404.4 ± 401.3 | 346.9 ± 261.2 | 0.452   |

Values are expressed as number of patients (percentage) or mean ± SD.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; ApoE, apolipoprotein E; BMI, body mass index; BUN, blood urea nitrogen; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; Hba1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp (a), lipoprotein (a); SBP, systolic blood pressure.
Table 2: Clinical outcomes.

| Variables          | CAD + CKD (n = 328) | CAD (n = 242) | CKD (n = 147) | P value  |
|-------------------|---------------------|---------------|---------------|----------|
| MACE              | 183 (55.8)          | 115 (47.5)    | 36 (24.5)     | <0.001   |
| Cardiovascular events | 181 (55.2)        | 110 (45.5)    | 36 (24.5)     | <0.001   |
| All-cause death   | 80 (24.4)           | 26 (10.7)     | 9 (6.1)       | <0.001   |
| Cardiac death     | 67 (20.4)           | 22 (9.1)      | 4 (2.7)       | <0.001   |

Values are expressed as number of patients (percentage).

CAD, coronary artery disease; CKD, chronic kidney disease; MACE, major adverse cardiovascular event.

3.2. Clinical Outcomes. The CAD + CKD group was found to have cardiovascular events (55.2%), all-cause death (24.4%), and cardiac death (20.4%) with the highest frequency among the three groups (Table 2). The incidence of MACE was lowest in the CKD group (24.5%) compared with that of the CAD + CKD group (55.8%) and the CAD group (47.5%) (P < 0.001).

Figure 1 shows the MACE-free survival curves through 8 years for the three groups. The log-rank test revealed that the MACE-free survival rate in the CAD + CKD group was the lowest compared with that of the CAD group and the CKD group; the lowest rate occurred in the CAD + CKD group and the highest in the CKD-only group (P < 0.001). The median observation period for the CAD + CKD, CAD, and CKD groups was 67 months (interquartile range [IQR]: 57–77), 76 months (IQR: 69–81), and 75.5 months (IQR: 61.5–80.25), respectively.

3.3. Effects of Statins on Clinical Outcomes. We compared the effects of statins on the clinical outcomes of the three groups of patients (Table 3). The data revealed that long-term statin therapy was much more effective in the CAD + CKD patients compared with CAD-only and CKD-only patients. In the CAD-only patients, long-term statins exerted no significant effect on the MACE rate, while the CAD + CKD patients taking long-term statins showed a 20.5% reduction in the MACE rate (P < 0.001; Table 3). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD-only patients (reduction of about 11% in mortality rates, P < 0.05), but for the CAD + CKD patients, the reduction in mortality rates (about 28% reduction) was more dramatic (P < 0.001). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.

3.4. Factors Affecting MACE. Univariate Cox regression analysis showed that group, age, gender, hypertension, smoking, β-blockers, aspirin, statin discontinuation, baseline LDL-C, SBP, and DBP as well as total cholesterol, LDL-C, glucose, and SBP at final observation might affect the incidence of MACE (Table 4). Multivariate Cox regression analysis, including the significant predictors above and the marginally significant predictor of myocardial infarction in the univariate model, showed that group, smoking, statin discontinuation, baseline LDL-C, and SBP as well as total cholesterol, SBP, and glucose at final observation were independent predictors of MACE (Table 5). The CKD-only group had the lowest risk of MACE (versus CAD + CKD group: HR 0.42, 95% CI 0.31–0.57, P < 0.001; versus CAD-only group: HR 0.16, 95% CI 0.07–0.38, P < 0.001) (Table 5). The findings indicate that the CKD group had the best long-term survival status, followed by the CAD group, and the CAD + CKD group had the worst long-term survival.

4. Discussion

Our study is the first to compare the effects of long-term statin treatment in CAD patients with or without CKD and CKD-only patients in China. In the current study, we show that, among the Chinese CAD patients, the rate of CKD was as high as 57.5% (328/570). Reduced eGFR (<60 mL/min/1.73 m²) in CAD patients significantly increased the incidence of MACE and cardiovascular events. In particular, the all-cause and cardiac death rates of the CAD + CKD patients were about twice as high as the CAD-only patients. Thus, just as CKD is a risk factor for CAD, CAD is a risk factor for CKD, emphasizing that CAD and CKD are closely associated diseases with a reciprocal adverse impact. Our data show that long-term statin therapy can significantly improve the clinical outcomes of the CAD patients without CKD in terms of mortality (about a 10% reduction) but not the MACE rate. For the CAD + CKD patients, however, the treatment effect of statins was much more dramatic, with remarkable reductions in the MACE rate (20.5%), all-cause death (28.6%), and
Few studies have examined the effects of long-term statins on clinical outcomes of CAD patients with or without renal insufficiency after coronary revascularization, and no such data from China were previously available. Moreover, to our knowledge, this is the first study in any location to have compared the effects of long-term statin therapy in the three groups of patients (CAD with or without CKD and CKD only). Kaneko et al. [20] studied the effects of long-term statins on CAD patients with renal insufficiency but did not include the CAD-only and CKD-only patients. Another Japanese group [21] compared the effects of statins on the clinical outcomes of CAD patients with or without renal insufficiency; however, there was no CKD-only patient group in their investigation, and the duration of statin treatment was shorter (3 years). Longer-term statin therapy may exert more significant treatment effects, and our results show that the extent of reduction in MACE, all-cause deaths, and cardiac deaths appears to be more dramatic compared with the Japanese studies. Noticeably, all CAD patients in our study, with or without CKD, had remarkably higher rates of MACE and fatal events compared with those in Japan; these higher rates would be subject to more significant treatment effects of statins. This suggests that the Chinese CAD patients are substantially different from those in Japan. Possible reasons for the high morbidity and mortality in China include worse economic conditions, heavier labor, and insufficient medical care. Thus, in CAD patients with worse clinical outcomes like in China, long-term statin therapy can exert more dramatic treatment effects, and measures should be taken to enhance adherence to statins.

A surprising finding is that the CKD patients without CAD had very low all-cause or cardiac mortality, and statin therapy did not have a significant impact on the cardiovascular events and mortality rates. Statin treatment has been shown to be beneficial for CKD patients not undergoing dialysis [13, 15, 22, 23]; however, previous studies have not separated CKD patients with or without CVD. In the current study, we selectively analyzed the CKD patients who did not have CVD at registration; these patients did not develop significantly increased cardiovascular events and mortality rates during the long follow-up period nor did they show an effective response to statin treatment. Thus, CKD patients free of CVD at baseline appear to have an excellent prognosis and, therefore, may not need statin treatment. This finding may provide a significant guideline regarding statins in CKD patients, and it warrants larger scale studies across multiple clinical centers in China.

Table 3: Effects of statins on clinical outcomes of different group of patients.

| Variables       | Long-term statins | No statin | Extent of reduction | P value |
|-----------------|-------------------|-----------|---------------------|---------|
| **CAD-only patients** |                   |           |                     |         |
| MACE            | 89/197 (45.2%)    | 21/45 (46.7%) | 1.5%                | 0.987   |
| All-cause death | 17/197 (8.6%)     | 9/45 (20%)  | 11.4%               | 0.049   |
| Cardiac death   | 14/197 (7.1%)     | 8/45 (17.8%) | 10.7%               | 0.049   |
| **CAD + CKD patients** |                |           |                     |         |
| MACE            | 77/170 (45.3%)    | 104/158 (65.8%) | 20.5%               | <0.001  |
| All-cause death | 18/170 (10.6%)    | 62/158 (39.2%) | 28.6%               | <0.001  |
| Cardiac death   | 12/170 (7.1%)     | 55/158 (34.8%) | 27.7%               | <0.001  |
| **CKD-only patients** |                |           |                     |         |
| MACE            | 14/41 (34.1%)     | 22/106 (20.8%) | −13.3%              | 0.142   |
| All-cause death | 2/41 (4.9%)       | 7/106 (6.6%) | 1.7%                | 0.99    |
| Cardiac death   | 0/41 (0%)         | 4/106 (3.8%) | 3.8%                | 0.48    |

CAD, coronary artery disease; CKD, chronic kidney disease; MACE, major adverse cardiovascular event.

In patients with stage 5 CKD, Pennell and colleagues found that the prevalence of dyslipidemia was 82%, which was characterized by raised triglycerides and very-low-density lipoproteins and decreased levels of high-density lipoproteins [27]. Due to increased oxidative stress, furthermore, CKD is associated with accelerated progression of atherosclerosis [28]. Thus, there are reasons to consider statin
### Table 4: Unadjusted predictors for MACE.

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| CKD versus CAD + CKD| 0.43         | (0.34, 0.55)| <0.001 |
| CKD versus CAD      | 0.14         | (0.07, 0.28)| <0.001 |
| Age (years)         | 1.03         | (1.01, 1.04)| <0.001 |
| Male (versus female)| 0.78         | (0.61, 0.99)| 0.045   |
| Hypertension        | 1.42         | (1.11, 1.82)| <0.01   |
| Diabetes mellitus   | 1.21         | (0.94, 1.54)| 0.134   |
| Smoking             | 1.42         | (1.13, 1.79)| <0.01   |
| Myocardial infarction| 1.25      | (1.0, 1.57)| 0.055   |
| Angina pectoris     | 1.13         | (0.90, 1.42)| 0.28    |
| Stroke              | 1.44         | (0.91, 2.27)| 0.118   |
| Ejection fraction   | 0.99         | (0.98, 1.00)| 0.165   |
| Calcium-channel blocker| 1.13    | (0.88, 1.44)| 0.346   |
| ACEI                | 1            | (0.80, 1.26)| 0.983   |
| ARB                 | 0.94         | (0.75, 1.19)| 0.627   |
| β-blocker           | 1.49         | (1.14, 1.94)| <0.01   |
| Loop diuretic       | 1.15         | (0.79, 1.66)| 0.475   |
| Aspirin             | 2.21         | (1.40, 3.48)| <0.01   |

**Clinical parameters at baseline**

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| Total cholesterol (mmol/l) | 0.96   | (0.87, 1.05)| 0.319   |
| LDL-C (mmol/l)       | 1.002        | (1.001, 1.003)| <0.001 |
| HDL-C (mmol/l)       | 0.78         | (0.52, 1.19)| 0.251   |
| Triglycerides (mmol/l)| 0.98     | (0.88, 1.08)| 0.65    |
| HbA1c (%)            | 0.98         | (0.88, 1.09)| 0.728   |
| Glucose (mmol/l)     | 1            | (0.99, 1.01)| 0.614   |
| SBP (mmHg)           | 0.994        | (0.99, 1.0)| 0.011   |
| DBP (mmHg)           | 0.99         | (0.98, 1.0)| 0.011   |

**Clinical parameters at final observation**

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| Total cholesterol (mmol/l) | 1.31   | (1.19, 1.44)| <0.001 |
| LDL-C (mmol/l)       | 1.26         | (1.13, 1.41)| <0.001 |
| HDL-C (mmol/l)       | 1.04         | (0.68, 1.60)| 0.846   |
| Triglycerides (mmol/l)| 1.09     | (0.97, 1.21)| 0.135   |
| HbA1c (%)            | 1.02         | (0.92, 1.14)| 0.702   |
| Glucose (mmol/l)     | 1.1          | (1.06, 1.15)| <0.001 |
| SBP (mmHg)           | 1.006        | (1.0, 1.01)| 0.046   |
| DBP (mmHg)           | 0.997        | (0.99, 1.01)| 0.545   |
| Statins              | 0.247        | (0.19, 0.38)| <0.001 |

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; SBP, systolic blood pressure.

### Table 5: Adjusted determinants of MACE.

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| Group               |              |            |         |
| CKD versus CAD + CKD| 0.42         | (0.31, 0.57)| <0.001 |
| CKD versus CAD      | 0.16         | (0.07, 0.38)| <0.001 |
| Age (years)         | 1.01         | (1.0, 1.03)| 0.065   |
| Male (versus female)| 1.23         | (0.91, 1.68)| 0.183   |
| Hypertension        | 1.29         | (0.99, 1.68)| 0.061   |
| Smoking             | 1.58         | (1.19, 2.08)| 0.002   |
| Myocardial infarction| 1.04      | (0.80, 1.34)| 0.791   |
| β-blocker           | 1.13         | (0.83, 1.53)| 0.449   |
| Aspirin             | 1.19         | (0.72, 1.98)| 0.505   |

**Clinical parameters at baseline**

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| LDL-C (mmol/l)       | 1.001        | (1.0, 1.002)| 0.008   |
| SBP (mmHg)           | 0.99         | (0.98, 0.994)| <0.001 |
| DBP (mmHg)           | 1            | (0.99, 1.01)| 0.88    |

**Clinical parameters at final observation**

|                     | Hazard ratio | 95% CI     | P value |
|---------------------|--------------|------------|---------|
| Total cholesterol (mmol/l) | 1.38   | (1.13, 1.68)| 0.002   |
| LDL-C (mmol/l)       | 0.89         | (0.70, 1.13)| 0.334   |
| SBP (mmHg)           | 1.01         | (1.001, 1.013)| 0.023  |
| Glucose (mmol/l)     | 1.06         | (1.01, 1.12)| 0.03    |
| Statins              | 0.25         | (0.2, 0.38)| <0.001 |

CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; SBP, systolic blood pressure.

Treatment in CKD patients. There are a number of studies exploring the effect of statins in different CKD stages, but the findings are inconclusive. On one hand, there is evidence in support of the effect of statins in reducing cardiovascular events in CKD patients, irrespective of the stage [23, 29]. On the other hand, Palmer and colleagues indicated that statins had little effect in patients undergoing dialysis [13]. The majority of patients with CAD + CKD in the current study had end-stage renal disease with an enhanced predisposition to accelerated atherosclerosis and, thus, would derive the greatest benefit from the statin therapy.

Limitations of the current study include a lack of records on statin types and dosage that precluded an analysis of the effect of these factors on clinical outcomes and lack of information on patients with CKD stages 1 to 4 that precluded an analysis on the effect of statins in different CKD stages. Therefore, a more carefully controlled prospective study would be necessary to achieve this purpose. Another limitation is that it is a clinical study from a single center. Future studies that include a larger cohort of patients from multiple centers in China are necessary to corroborate our findings and to support their generalizability.
5. Conclusions

This study is the first to compare clinical outcomes in Chinese CAD patients with or without CKD and in CKD-only patients treated with long-term statins; it provides new insights about the appropriate treatment of these three groups of patients. More than half of the CAD patients in this study had chronic kidney disease, which greatly contributed to the adverse clinical outcomes of the CAD patients. Long-term statin therapy significantly improved the mortality rate but not the MACE rate of the CAD patients without renal insufficiency, while it more dramatically reduced the MACE and mortality rates of the CAD patients with concomitant CKD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.

Disclosure

Huiling Huang and Chunmei Zeng are co-first authors of the paper. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. No relationship with industry exists in the present study.

Conflict of Interests

The authors declare that there is no conflict of interests.

Authors’ Contribution

Huiling Huang and Chunmei Zeng are responsible for case collection and drafting the paper. Yuedong Ma and Yili Chen participated in the follow-up. Cong Chen and Chen Liu participated in the design of the study and performed the statistical analysis. Yugang Dong conceived the study and participated in its design and coordination and helped to draft the paper. All authors read and approved the final paper.

Acknowledgments

The study was supported by the National Natural Science Foundation of China (Grant no. 81200173) and the Specialized Research Fund for the Doctoral Program of Higher Education (Grant no. 20120171120078).

References

[1] V. Fuster, B. B. Kelly, and R. Vedanthan, "Promoting global cardiovascular health: moving forward," Circulation, vol. 123, no. 15, pp. 1671–1678, 2011.
[2] M. J. Sarnak, A. S. Levy, A. C. Schoolwerth et al., "Kidney disease as a risk factor for development of cardiovascular disease: a statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention," Circulation, vol. 108, no. 17, pp. 2154–2169, 2003.
[3] P. Yerram, P. R. Karuparthi, L. Hesemann, J. Horst, and A. Whaley-Connell, "Chronic kidney disease and cardiovascular risk," Journal of the American Society of Hypertension, vol. 1, no. 3, pp. 178–184, 2007.
[4] S. Said and G. T. Hernandez, "The link between chronic kidney disease and cardiovascular disease," Journal of Nephropathology, vol. 3, pp. 99–104, 2014.
[5] G. T. Hernandez, M. Sippel, and D. Mukherjee, "Interrelationship between chronic kidney disease and risk of cardiovascular diseases," Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 11, no. 1, pp. 38–43, 2013.
[6] A. Briassoulis and G. L. Bakri, "Chronic kidney disease as a coronary artery disease risk equivalent," Current Cardiology Reports, vol. 15, no. 3, article 340, 2013.
[7] M. Tonelli, P. Jose, G. Curhan, F. Sacks, E. Braunwald, and M. Pfleger, "Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial," British Medical Journal, vol. 332, article 1426, 2006.
[8] S. Wison, K. Foo, J. Cunningham et al., "Renal function and risk stratification in acute coronary syndromes," American Journal of Cardiology, vol. 91, no. 9, pp. 1051–1054, 2003.
[9] H. Reinecke, T. Trey, F. Matzkies, M. Fobker, G. Breithardt, and R. M. Schaefer, "Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions," Kidney International, vol. 63, no. 2, pp. 696–701, 2003.
[10] H. Yagi, M. Kawai, K. Komukai et al., "Impact of chronic kidney disease on the severity of initially diagnosed coronary artery disease and the patient prognosis in the Japanese population," Heart and Vessels, vol. 26, no. 4, pp. 370–378, 2011.
[11] E. J. Mills, P. Wu, G. Chong et al., "Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials," QJM, vol. 104, no. 2, pp. 109–124, 2011.
[12] F. C. Taylor, M. Huffman, and S. Ebrahim, "Statin therapy for primary prevention of cardiovascular disease," The Journal of the American Medical Association, vol. 310, no. 22, pp. 2451–2452, 2013.
[13] S. C. Palmer, J. C. Craig, S. D. Navaneethan, M. Tonelli, F. Pellegrini, and G. F. M. Strippoli, "Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis," Annals of Internal Medicine, vol. 157, no. 4, pp. 263–275, 2012.
[14] V. Shalev, G. Chodick, H. Silber, E. Kokia, J. Jan, and A. D. Heymann, "Continuation of statin treatment and all-cause mortality," Archives of Internal Medicine, vol. 169, no. 3, pp. 260–268, 2009.
[15] D. Nikolic, M. Banach, S. Nikfar et al., "A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?" International Journal of Cardiology, vol. 168, no. 6, pp. 5437–5447, 2013.
[16] G. Chodick, V. Shalev, Y. Gerber et al., "Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel," Clinical Therapeutics, vol. 30, no. 11, pp. 2167–2179, 2008.
[17] Y.-C. Ma, L. Zuo, J. H. Chen et al., "Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease," Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 2937–2944, 2006.
[18] G. Eknoyan, "Meeting the challenges of the new K/DOQI guidelines," American Journal of Kidney Diseases, vol. 41, no. 6, pp. S3–S10, 2003.
[19] X. Liu, S. Zhang, M. Liu et al., "Chinese guidelines for endovascular management of ischemic cerebrovascular diseases," Interventional Neurology, vol. 1, no. 3–4, pp. 171–184, 2013.
[20] H. Kaneko, J. Yajima, Y. Oikawa et al., "Effects of statin treatment in patients with coronary artery disease and chronic kidney disease," *Heart and Vessels*, vol. 29, no. 1, pp. 21–28, 2014.

[21] M. Natsuaki, Y. Furukawa, T. Morimoto, R. Sakata, and T. Kimura, "Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2)," *American Journal of Cardiology*, vol. 110, no. 11, pp. 1568–1577, 2012.

[22] J. A. Lardizabal and P. C. Deedwania, "Benefits of statin therapy and compliance in high risk cardiovascular patients," *Vascular Health and Risk Management*, vol. 6, no. 1, pp. 843–853, 2010.

[23] W. Hou, J. Lv, V. Perkovic et al., "Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis," *European Heart Journal*, vol. 34, no. 24, pp. 1807–1817, 2013, Review.

[24] F. J. Morrison, H. Zhang, S. Skentzos, M. Shubina, R. Bentley-Lewis, and A. Turchin, "Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease," *CardioRenal Medicine*, vol. 4, no. 3-4, pp. 225–233, 2014.

[25] B. C. Fellström, A. G. Jardine, R. E. Schmieder et al., "Roserivastatin and cardiovascular events in patients undergoing hemodialysis," *The New England Journal of Medicine*, vol. 360, no. 14, pp. 1395–1407, 2009.

[26] J. J. Kim, D. R. Langworthy, and E. K. Hennessey, "Clinical implications of statin therapy in patients undergoing hemodialysis," *American Journal of Health-System Pharmacy*, vol. 71, no. 9, pp. 703–710, 2014.

[27] P. Pennell, B. Leclercq, M. J. Delahunty, and B. A. J. Walters, "The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease," *Clinical Nephrology*, vol. 66, no. 5, pp. 336–347, 2006.

[28] S. P. M. Sundaram, S. Nagarajan, and A. J. M. Devi, "Chronic kidney disease—effect of oxidative stress," *Chinese Journal of Biology*, vol. 2014, Article ID 216210, 6 pages, 2014.

[29] G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., "Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials," *British Medical Journal*, vol. 336, no. 7645, pp. 645–651, 2008.